Supporting Information

Synthesis of Thermally Stable Geminal Dicationic Ionic Liquids and Related Ionic Compounds: An Examination of Physicochemical Properties by Structural Modification

Rahul A. Patil, Mohsen Talebi, Chengdong Xu, Sumit S. Bhawal, Daniel W. Armstrong *

Department of Chemistry and Biochemistry, The University of Texas at Arlington, 700 Planetarium Place, Arlington, Texas 76019-0065, United States

Table of Content		Page No.
1.	Methods of Analysis	2
2.	Synthesis of monocationic ILs	2
3.	Synthesis of dicationic ILs	3
4.	Characterization of ILs	7
5.	¹ H NMR spectra and ¹³ C NMR spectra	12

Methods of Analysis:

The monocationic ionic liquids and dicationic ionic liquids were characterized by electrospray ionization mass spectrometry (ESI-MS) for molecular weight. ESI-MS spectra were acquired by using a Finnigan LXQ (Thermo Fisher Scientific, San Jose, CA). ¹H NMR, ¹³C NMR and ³¹P NMR experiments were performed on 500 MHz JEOL Eclipse Plus 500 instrument for spectral analysis. Thermogravimetric analysis were performed using Shimadzu TGA-51 Thermogravimetric Analyzer (Kyoto, Kyoto Prefecture, Japan) for the stability testing. Samples (~10 mg) were placed in the platinum pans, and heated at 10 °C min⁻¹ from room temperature to $600 \,^{\circ}\text{C}$ in a nitrogen atmosphere (flow – 30mL min^{-1}). The decomposition temperature were determined at 1%, 5% and 15% weight loss. 5% weight loss of the sample which corresponds to 95% w value was considered as measure of thermal stability. The GC thermal stability measurements were made using Agilent 6890N Gas Chromatograph equipped with flame ionization detector (FID). The studies were performed ramping the column oven temperature from 100 to 450 °C at 1 °C min⁻¹ and using helium as carrier gas at flow rate of 1 mL min⁻¹. The injector and FID temperatures were set at 250 °C and 400 °C respectively. The DSC measurements were carried out on a Shimadzu DSC-60 (Kyoto, Kyoto Prefecture, Japan) differential scanning calorimeter (DSC). The samples (~ 10 mg) were sealed in aluminum pans, and then heated at rate of 10 °C min⁻¹ up to 500 °C. Melting points were determined using a Mel-Temp apparatus (Laboratory Devices, Cambridge, MA). Density was measured using 10 mL Kimble specific gravity pycnometer at 22 °C. Heptane was used as an immiscible solvent for these measurements. Kinematic viscosity was determined using a Cannon-Manning semimicro viscometer. All compounds synthesized in this study were tested for solubility with polar (water) and non-polar (heptane) solvent. This study was performed by placing a small amount (60-100 mg) of the compound in the solvent (15 mL) and through observation of whether the solute was miscible or immiscible in the solvent.

Synthesis of monocationic ILs:

Compounds **IL1**, **IL2**, **IL3**, **IL4**, **IL5**, **IL6**, **IL7**, and **IL8** were made through metathesis reactions of 1 molar equivalents of tributyltetradecylphosphonium chloride salt with 1 molar equivalents of bis(trifluoromethane)sulfonimide lithium (LiNTf₂), bis(pentafluoromethane)sulfonimide lithium (LiNPf₂), heptadecafluorooctanesulfonic acid

potassium salt (KPFOS), Iron (III) chloride(FeCl₃), tris(pentafluoroethyl)trifluorophosphate hydride (FAP), bis(2-ethylhexyl) sulfosuccinate sodium (NaAOT), 1-octanesulfonic acid sodium salt (NaOS), and potassium dodecafluoro-closo-dodecaborate (KB₁₂F₁₂), respectively. The reactions for all ILs were performed in water at room-temperature for 12 h with the exception of heptadecafluorooctanesulfonic acid potassium salt (KPFOS), which was performed at elevated temperature (110 °C) with oil-bath. Dichloromethane was added to the resulting solution to dissolve the target product. The aqueous layer was then removed and the organic layer washed three times with water to remove any starting material. Dichloromethane was then removed by rotary evaporation followed by vacuum drying over phosphorous pentoxide at 40 °C for 24 h. The procedure resulted in the pure monocationic ionic liquid.

Synthesis of dicationic ionic liquids:

Synthesis of dicationic ionic liquids involved two steps. First step involved a nucleophilic substitution reaction of imidazoles / pyrrolidones / phosphines with corresponding terminal dibromoalkanes to obtain bromide salt of dication. Second step was metathesis dibromodicationic salt with LiNTf₂ and KPFOS. In metathesis step bromide ions were exchanged by NTf_2^- or PFOS⁻ anions to obtain final product ILs and LiBr and KBr as side products.

Synthesis of imidazolium based Ionic Liquids

Procedure 1:

Step 1) **IL9, IL21 and IL 33** were made by refluxing 2 molar equivalents of 1-butyl-2methylimidazole with 1 molar equivalent of 1, 6-dibromohexane, 1, 9-dibromononane and 1, 12dibromododecane respectively in acetonitrile at 80 °C for 72 h.(Scheme 1) Rotary evaporation of solvent yielded the crude dibromodicationic salt. The salt was then dissolved in water and transferred to a separatory funnel and washed with dichloromethane (3×50 ml) to remove excess starting material. The aqueous layer containing dibromodications was then dried by rotary evaporation of water. Further, vacuum drying over phosphorous pentoxide at 40 °C for 24h resulted in the pure dibromodicationic salts. The products were then verified by mass spectrometry analysis. Step 2) For the synthesis of final products, the dibromodications synthesized in the first step were dissolved in water and reacted with 2 molar equivalents of $(\text{LiNTf}_2)(\text{Scheme 2})$. The solution was stirred for 24 h at room temperature. The metathesis process resulted in exchange of bromide anions with NTf₂⁻ anions. Following that, dichloromethane (40 mL) was added to the solution to extract NTf₂⁻ salt of the ionic liquid that has phase separated from the water. The lithium bromide and excess NTf₂⁻ were removed from the dichloromethane phase with successive extraction with water (3x40mL). Removal of dichloromethane through rotary evaporation followed by vacuum drying over P₂O₅ at 40 °C for 24 h resulted in the pure dicationic 1-butyl-2-methylimidazolium ILs with NTf₂⁻ counter anion. Procedure 2:

For the synthesis of **IL15**, **IL27** and **IL 39** with PFOS⁻ anion; dibromodications and heptadecafluorooctanesulfonic acid potassium salt (KPFOS) were dissolved in a mixture of methanol and water (1:1) and stirred for 12 h.(Scheme 2) The solvents were evaporated using rotary evaporation method and similar protocol as mentioned in Step 2 of procedure 1 was followed for the rest of the reaction workup.

Procedure 3:

For the synthesis of **IL10**, **IL22**, **IL34**, **IL15**, **IL28** and **IL40** similar protocol as procedure 1 and 2 was followed except 2 moles of 1, 2-dimethylimidazole used instead of 1-butyl-2-methylimidazole.

Synthesis of pyrrolidinium based Ionic Liquids:

Procedure 4:

For the synthesis of **IL11**, **IL23**, **IL35**, **IL17**, **IL29** and **IL41** similar protocol as procedure 1 and 2 was followed except 2 moles of 1-butylpyrrolidine was used instead of 1-butyl-2-methylimidazole.

Procedure 5:

For the synthesis of **IL12**, **IL24**, **IL36**, **IL18**, **IL30** and **IL42** similar protocol as procedure 1 and 2 was followed except 2 moles of N-methylpyrrolidine was used instead of 1-butyl-2-methylimidazole.



Scheme: 1 Synthesis of bromide salt of dication

Scheme: 2 Metathesis of bromide salts to synthesize dicationic ILs



Synthesis of phosphonium based ionic liquids:

Procedure 6:

Step 1) **IL13, IL25, IL37, IL19, IL31** and **IL43** were made by refluxing 2 molar equivalents of tripropylphosphine with 1 molar equivalent of 1,6-dibromohexane, 1,9-dibromononane and 1,12-dibromododecane respectively in acetonitrile at 80 °C for 72 h.(Scheme 1) The reaction was performed under inert argon condition to prevent oxidation of tripropylphosphine. Rotary evaporation of solvent yielded the crude dibromodicationic salt. Similar protocol as mentioned in Procedure 1 and 2 was followed for the rest of the reaction workup. Procedure 7:

Step 1) Compounds **IL14**, **IL26** and **IL38** were synthesized by refluxing 2 molar equivalents of triphenylphosphine with 1 molar equivalent of 1,6-dibromohexane, 1,9-dibromononane and 1,12-dibromododecane respectively in N,N-Dimethylformamide at 95 °C for 72 h.(Scheme 1) Rotary evaporation of solvent yielded the crude dibromodicationic salt. The salt was then washed with five aliquots of ethyl acetate $(3 \times 50 \text{ mL})$ to remove unreacted starting material. The rotary evaporation of solvent and further vacuum drying over phosphorous pentoxide resulted in the pure dibromodicationic salts. Obtained products then verified by mass spectrometry analysis. Step 2) For the synthesis of final products, the dibromodications synthesized in the first step were dissolved in methanol and water (1:1) and reacted with 2 molar equivalents of (LiNTf_2) . The solution was stirred for 24 h at room temperature.(Scheme 2) This metathesis process resulted in final IL with bromide anions exchanged with NTf_2^- anions. The solvents were evaporated using rotary evaporation method. The crude NTf₂⁻ salt was dissolved in dichloromethane. The lithium bromide and excess NTf₂⁻ were removed from the dichloromethane phase with successive extractions with water (3x40 mL). Removal of dichloromethane through rotary evaporation followed by vacuum drying over P2O5 at 40 °C for 24 h resulted in the pure dicationic triphenylphosphonium ILs with NTf_2^- counter anion. Procedure 8:

To synthesize compounds **IL20**, **IL32** and **IL44**; dibromodications and heptadecafluorooctanesulfonic acid potassium salt (KPFOS) were dissolved in a mixture of methanol and water (1:1) and stirred for 24 h. The solvents were evaporated using rotary evaporation method and similar protocol as mentioned in Step 2 of Procedure 7 was followed for the rest of the reaction workup.

Characterization of ILs:

Characterization IL 9:

¹H NMR (500Hz; DMSO; ppm): δ 1.29 (br. s, 4H); δ 1.72 (m, 4H); δ 2.61 (s, 6H); δ 4.09 (t, $J_{\text{H-H}}$ = 7.45 Hz, 4H); δ 5.40 (s, 4H); δ 7.31 (m, 4H); δ 7.40 (m, 6H); δ 7.72 (dd, $J_{\text{H-H}}$ = 1.72 Hz, $J_{\text{H-H}}$ = 15.42 Hz, 4H). ¹³C NMR (500Hz; DMSO; ppm): δ 9.34; 25.02; 28.68; 47.87; 50.92; 118.12; 120.68; 121.48; 121.64; 127.64; 128.44; 128.94; 134.44; 143.99. ESI-MS: m/2z (+) 214.08; m/z (-) 279.89

Characterization IL 10:

¹H NMR (500Hz; DMSO; ppm): δ 1.28 (br. s, 4H); δ 1.68 (m, 4H); δ 2.56 (s, 6H); δ 3.74 (s, 6H); δ 4.09 (t, $J_{\text{H-H}} = 7.29$ Hz, 4H), δ 7.61 (dd, $J_{\text{H-H}} = 2.19$ Hz, $J_{\text{H-H}} = 2.79$ Hz, 4H). ¹³C NMR (500Hz; DMSO; ppm): δ 9.35; 25.30; 29.22; 34.91; 47.63; 115.99; 118.46; 121.03; 121.07; 122.58; 144.47. ESI-MS: m/2z (+) 138.12; m/z (-) 279.80

Characterization IL 11:

¹H NMR (300Hz; DMSO; ppm): δ 0.90 (t, J_{H-H} = 7.29 Hz, 6H); δ 1.30 (m, 8H); δ 1.58 (m, 8H); δ 2.02 (br. s, 8H); δ 3.16 (m, 8H); δ 3.42 (m, 8H). ¹³C NMR (300Hz; DMSO; ppm): δ 13.94; 19.73; 21.88; 22.88; 24.97; 25.88; 59.01; 62.64; 117.88; 122.15. ESI-MS: m/2z (+) 169.17; m/z (-) 279.80

Characterization IL 12:

¹H NMR (500Hz; DMSO; ppm): δ 1.33 (br. s, 4H); δ 1.71 (m, 4H); δ 2.08 (m, 8H); δ 2.98 (s, 6H); δ 3.27 (m, 4H); 3.48 (m, 8H). ¹³C NMR (500Hz; DMSO; ppm): δ 21.36; 23.06; 25.75; 47.78; 63.20; 63.73; 115.98;118.51; 121.07; 123.65. ESI-MS: m/2z (+) 127.14; m/z (-) 279.85

Characterization IL 13:

¹H NMR (300Hz; DMSO; ppm): δ 0.99 (dt, J_{H-H} = 1.11 Hz, J_{H-H} = 7.19 Hz 18H); δ 1.47 (m, 20H); δ 2.13 (m, 16H). ¹³C NMR (300Hz; DMSO; ppm): δ 15.17; 15.22; 15.60; 15.82; 17.77; 18.40; 19.76; 20.38; 21.01; 29.82; 30.02; 117.89; 122.15. ESI-MS: m/2z (+) 202.25; m/z (-) 279.83

Characterization IL 14:

¹H NMR (300Hz; DMSO; ppm): δ 1.45 (br. s, 8H); δ 3.48 (m, 4H); δ 7.76 (m, 24H); δ 7.87 (m, 6H). ¹³C NMR (300Hz; DMSO; ppm): δ 20.98; 22.00; 22.06; 29.33; 29.55; 117.89; 118.44; 119.57; 122.15; 130.68; 130.86; 134.02; 134.15; 135.45. ESI-MS: m/2z (+) 304.25; m/z (-) 279.85

Characterization IL 15:

¹H NMR (500Hz; DMSO; ppm): δ 1.29 (br. s, 4H); δ 1.72 (m, 4H); δ 2.59 (s, 6H); δ 4.09 (t, $J_{\text{H-H}}$ = 7.45 Hz, 4H); δ 5.41 (s, 4H); δ 7.40 (m, 10H); δ 7.73 (dd, $J_{\text{H-H}}$ = 2.25 Hz, $J_{\text{H-H}}$ = 7.45 Hz, 4H). ¹³C NMR (500Hz; DMSO; ppm): δ 9.67; 25.32; 28.99; 48.00; 51.02; 121.80; 121.94; 127.98; 128.71; 129.23; 134.78; 144.33. ESI-MS: m/2z (+) 214.15; m/z (-) 498.89

Characterization IL 16:

¹H NMR (300Hz; DMSO; ppm): δ 1.23 (br. s, 4H); δ 1.66 (m, 4H); δ 2.54 (s, 6H); δ 3.74 (s, 6H); δ 4.06 (t, $J_{\text{H-H}} = 7.30$ Hz, 4H), δ 7.60 (dd, $J_{\text{H-H}} = 2.04$ Hz, $J_{\text{H-H}} = 4.8$ Hz, 4H). ¹³C NMR (300Hz; DMSO; ppm): δ 9.67; 25.56; 29.49; 35.18; 47.88; 121.35; 122.84; 144.77. ESI-MS: m/2z (+) 138.17; m/z (-) 498.84

Characterization IL 17:

¹H NMR (300Hz; DMSO; ppm): δ 0.88 (t, J_{H-H} = 7.24 Hz, 6H); δ 1.29 (m, 8H); δ 1.57 (m, 8H); δ 2.02 (br. s, 8H); δ 3.16 (m, 8H); δ 3.43 (m, 8H). ¹³C NMR (300Hz; DMSO; ppm): δ 14.22; 20.09; 22.25; 23.21; 25.36; 26.21; 59.40; 63.00. ESI-MS: m/2z (+) 169.18; m/z (-) 498.84

Characterization IL 18:

¹H NMR (300Hz; DMSO; ppm): δ 1.32 (br. s, 4H); δ 1.68 (m, 4H); δ 2.05 (m, 8H); δ 2.94 (s, 6H); δ 3.25 (m, 4H); 3.42 (m, 8H). ¹³C NMR (300Hz; DMSO; ppm): δ 21.58; 23.26; 25.97; 48.00; 63.40; 63.93. ESI-MS: m/2z (+) 127.17; m/z (-) 498.89

Characterization IL 19:

¹H NMR (300Hz; DMSO; ppm): δ 0.98 (dt, $J_{H-H} = 0.90$ Hz, $J_{H-H} = 7.24$ Hz 18H); δ 1.47 (m, 20H); δ 2.13 (m, 16H). ¹³C NMR (500Hz; DMSO; ppm): δ 15.19; 15.22; 15.70; 15.83; 18.21; 19.88; 20.25; 21.01; 21.04; 29.93. ESI-MS: m/2z (+) 202.25; m/z (-) 498.85

Characterization IL 20:

¹H NMR (300Hz; DMSO; ppm): δ 1.45 (br. s, 8H); δ 3.48 (m, 4H); δ 7.75 (m, 24H); δ 7.86 (m, 6H). ¹³C NMR (300Hz; DMSO; ppm): δ 20.27; 20.93; 22.00; 29.29; 29.51; 118.44; 119.58; 130.67; 130.84; 134.01; 134.15. ESI-MS: m/2z (+) 304.23; m/z (-) 498.89

Characterization IL 21:

¹H NMR (300Hz; DMSO; ppm): δ 1.22 (br. s, 10H); δ 1.69 (m, 4H); δ 2.56 (s, 6H); δ 4.06 (t, $J_{\text{H-H}} = 7.38$ Hz, 4H); δ 5.38 (s, 4H); δ 7.29 (m, 4H); δ 7.38 (m, 6H); δ 7.70 (dd, $J_{\text{H-H}} = 2.11$ Hz, $J_{\text{H-H}} = 5.35$ Hz, 4H). ¹³C NMR (500Hz; DMSO; ppm): δ 9.69; 25.91; 28.68; 29.01; 29.24; 47.97; 50.92; 115.94; 118.51; 121.07; 121.84; 121.98; 123.62; 127.98; 128.77; 129.29; 134.79; 144.32. ESI-MS: m/2z (+) 235.39; m/z (-) 279.85

Characterization IL 22:

¹H NMR (500Hz; DMSO; ppm): δ 1.26 (br. s, 10H); δ 1.68 (m, 4H); δ 2.56 (s, 6H); δ 3.74 (s, 6H); δ 4.08 (t, $J_{\text{H-H}} = 7.45$ Hz, 4H), δ 7.61 (dd, $J_{\text{H-H}} = 2.02$ Hz, $J_{\text{H-H}} = 10.57$ Hz, 4H). ¹³C NMR (500Hz; DMSO; ppm): δ 9.39; 25.91; 28.78; 29.08; 29.51; 34.95; 47.84; 115.99; 118.55; 121.10; 121.15; 122.63; 123.66; 144.51. ESI-MS: m/2z (+) 159.23; m/z (-) 279.79

Characterization IL 23:

¹H NMR (500Hz; DMSO; ppm): δ 0.93 (t, J_{H-H} = 7.42 Hz, 6H); δ 1.30 (m, 14H); δ 1.60 (m, 8H); δ 2.04 (br. s, 8H); δ 3.17 (m, 8H); δ 3.45 (m, 8H). ¹³C NMR (500Hz; DMSO; ppm): δ 13.77; 19.80; 21.68; 22.77; 24.75; 26.20; 28.79; 58.74; 58.96; 62.39; 118.48; 121.08. ESI-MS: m/2z (+) 190.17; m/z (-) 279.85

Characterization IL 24:

¹H NMR (500Hz; DMSO; ppm): δ 1.30 (br. s, 10H); δ 1.69 (m, 4H); δ 2.08 (m, 8H); δ 2.96 (s, 6H); δ 3.28 (m, 4H); 3.44 (m, 8H). ¹³C NMR (500Hz; DMSO; ppm): δ 21.35; 23.25; 26.19; 28.74; 28.93; 47.77; 63.44; 63.73; 115.98;118.54; 121.09; 123.65. ESI-MS: m/2z (+) 148.25; m/z (-) 279.85

Characterization IL 25:

¹H NMR (500Hz; DMSO; ppm): δ 1.01 (t, J_{H-H} = 7.42 Hz, 18H); δ 1.28 (br. s, 6H); δ 1.37 (m, 4H); δ 1.50 (m, 16H); δ 2.15 (m, 16H). ¹³C NMR (500Hz; DMSO; ppm): δ 15.03; 15.07; 15.52; 15.65; 17.82; 18.19; 19.75; 20.13; 21.00; 28.63; 28.98; 30.49; 30.61; 115.97; 121.14; 123.70. ESI-MS: m/2z (+) 223.35; m/z (-) 279.85

Characterization IL 26:

¹H NMR (500Hz; DMSO; ppm): δ 1.18 (m, 6H); δ 1.46 (m,8H); δ 3.53 (m, 4H); δ 7.82 (m, 30H). ¹³C NMR (500Hz; DMSO; ppm): δ 20.29; 20.69; 22.05; 28.36; 28.75; 30.08; 30.20; 118.55; 119.22; 121.09; 130.50; 130.59; 133.86; 133.93; 135.19. ESI-MS: m/2z (+) 325.25; m/z (-) 279.83

Characterization IL 27:

¹H NMR (300Hz; DMSO; ppm): δ 1.22 (br. s, 10H); δ 1.69 (m, 4H); δ 2.59 (s, 6H); δ 4.08 (t, $J_{H-H} = 7.38$ Hz, 4H); δ 5.39 (s, 4H); δ 7.33 (m, 10H); δ 7.72 (dd, $J_{H-H} = 2.20$ Hz, $J_{H-H} = 3.55$ Hz, 4H). ¹³C NMR (300Hz; DMSO; ppm): δ 9.99; 26.14; 28.92; 29.27; 29.50; 48.19; 51.12; 122.10; 122.22; 128.26; 128.98; 129.51; 135.09; 144.59. ESI-MS: m/2z (+) 235.35; m/z (-) 498.89

Characterization IL 28:

¹H NMR (500Hz; DMSO; ppm): δ 1.26 (br. s, 10H); δ 1.68 (m, 4H); δ 2.56 (s, 6H); δ 3.74 (s, 6H); δ 4.08 (t, $J_{H-H} = 7.21$ Hz, 4H), δ 7.62 (dd, $J_{H-H} = 2.30$ Hz, $J_{H-H} = 9.70$ Hz, 4H). ¹³C NMR

(500Hz; DMSO; ppm): δ 9.43; 25.93; 28.81; 29.10; 29.53; 34.98; 47.86; 121.15; 122.63; 123.66; 144.53. ESI-MS: m/2z (+) 159.29; m/z (-) 498.89

Characterization IL 29: ESI-MS: m/2z (+) 190.17; m/z (-) 498.89

Characterization IL 30: ESI-MS: m/2z (+) 148.26; m/z (-) 498.86

Characterization IL 31: ESI-MS: m/2z (+) 223.37; m/z (-) 498.85

Characterization IL 32: ¹H NMR (300Hz; DMSO; ppm): δ 1.14 (m, 6H); δ 1.42 (m, 8H); δ 3.51 (m, 4H); δ 7.78 (m, 30H). ¹³C NMR (300Hz; DMSO; ppm): δ 20.33; 20.99; 22.24; 28.56; 28.95; 30.20; 30.42; 118.52; 119.66; 130.65; 130.82; 134.02; 134.16; 135.38. ESI-MS: m/2z (+) 325.23; m/z (-) 498.89

Characterization IL 33: ESI-MS: m/2z (+) 256.25; m/z (-) 279.86

Characterization IL 34:

¹H NMR (500Hz; DMSO; ppm): δ 1.24 (br. s, 16H); δ 1.68 (m, 4H); δ 2.56 (s, 6H); δ 3.74 (s, 6H); δ 4.08 (t, $J_{\text{H-H}} = 7.45$ Hz, 4H), δ 7.61 (dd, $J_{\text{H-H}} = 1.97$ Hz, $J_{\text{H-H}} = 13.02$ Hz, 4H). ¹³C NMR (500Hz; DMSO; ppm): δ 9.37; 25.92; 28.84; 29.21; 29.27; 29.50; 34.93; 47.81; 115.98; 118.52; 121.07; 121.13; 122.59; 123.66; 144.48. ESI-MS: m/2z (+) 180.17; m/z (-) 279.83

Characterization IL 35: ESI-MS: m/2z (+) 211.25; m/z (-) 279.86

Characterization IL 36: ¹H NMR (500Hz; DMSO; ppm): δ 1.29 (br. s, 16H); δ 1.69 (m, 4H); δ 2.08 (m, 8H); δ 2.96 (s, 6H); δ 3.28 (m, 4H); 3.44 (m, 8H). ¹³C NMR (500Hz; DMSO; ppm): δ 21.34; 23.24; 26.21; 28.82; 29.13; 29.22; 47.76; 63.48; 63.73; 115.98; 118.55; 121.10; 123.66. ESI-MS: m/2z (+) 169.18; m/z (-) 279.86

Characterization IL 37: ¹H NMR (500Hz; DMSO; ppm): δ 1.01 (t, *J*_{H-H} = 7.42 Hz, 18H); δ 1.26 (m, 12H); δ 1.37 (m, 4H); δ 1.50 (m, 16H); δ 2.14 (m, 16H). ¹³C NMR (500Hz; DMSO; ppm): δ 14.96; 15.00; 15.47; 15.60; 17.73; 18.11; 19.68; 20.05; 20.90; 28.59; 29.14; 29.34; 30.42; 30.55; 115.95; 118.52; 121.07; 123.50. ESI-MS: m/2z (+) 244.25; m/z (-) 279.80

Characterization IL 38: ESI-MS: m/2z (+) 346.25; m/z (-) 279.84

Characterization IL 39: ESI-MS: m/2z (+) 256.25; m/z (-) 498.84

Characterization IL 40: ¹H NMR (300Hz; DMSO; ppm): δ 1.25 (br. s, 16H); δ 1.70 (m, 4H); δ 2.58 (s, 6H); δ 3.76 (s, 6H); δ 4.10 (t, *J*_{H-H} = 7.38 Hz, 4H), δ 7.63 (dd, *J*_{H-H} = 2.07 Hz, *J*_{H-H} = 7.89 Hz, 4H). ¹³C NMR (500Hz; DMSO; ppm): δ 9.19; 25.75; 28.68; 29.05; 29.11; 29.36; 34.75; 47.63; 120.96; 122.42; 144.35. ESI-MS: m/2z (+) 180.15; m/z (-) 498.89

Characterization IL 41: ESI-MS: m/2z (+) 211.26; m/z (-) 498.86

Characterization IL 42: ESI-MS: m/2z (+) 169.17; m/z (-) 498.86

Characterization IL 43: ESI-MS: m/2z (+) 244.37; m/z (-) 498.85

Characterization IL 44: ESI-MS: m/2z (+) 346.235; m/z (-) 498.89









































.....



























































